These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 22451032)

  • 1. Interleukin-6 and cytochrome-P450, reason for concern?
    Kim S; Östör AJ; Nisar MK
    Rheumatol Int; 2012 Sep; 32(9):2601-4. PubMed ID: 22451032
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of Interferons and Biological Drug Inhibitors of IL-2 and IL-6 on Small-Molecule Drug Metabolism Through the Cytochrome P450 System.
    White CM; Sicignano DJ; Smith K
    Ann Pharmacother; 2022 Feb; 56(2):170-180. PubMed ID: 34078115
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disease-Drug Interaction of Sarilumab and Simvastatin in Patients with Rheumatoid Arthritis.
    Lee EB; Daskalakis N; Xu C; Paccaly A; Miller B; Fleischmann R; Bodrug I; Kivitz A
    Clin Pharmacokinet; 2017 Jun; 56(6):607-615. PubMed ID: 27722854
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tocilizumab (Actemra).
    Sheppard M; Laskou F; Stapleton PP; Hadavi S; Dasgupta B
    Hum Vaccin Immunother; 2017 Sep; 13(9):1972-1988. PubMed ID: 28841363
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Subcutaneous tocilizumab for the treatment of rheumatoid arthritis.
    Mitchell E; Jones G
    Expert Rev Clin Immunol; 2016; 12(2):103-14. PubMed ID: 26629984
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The efficacy and safety of reinstitution of tocilizumab in patients with relapsed active rheumatoid arthritis after long-term withdrawal of tocilizumab: retreatment of patients with rheumatoid arthritis with novel anti-IL-6 receptor antibody after a long-term interval following SAMURAI: the RONIN study.
    Sagawa A
    Mod Rheumatol; 2011 Aug; 21(4):352-8. PubMed ID: 21347804
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety of subcutaneous versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with rheumatoid arthritis.
    McLaughlin M; Östör A
    Expert Opin Drug Saf; 2015 Mar; 14(3):429-37. PubMed ID: 25553607
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel scoring system based on common laboratory tests predicts the efficacy of TNF-inhibitor and IL-6 targeted therapy in patients with rheumatoid arthritis: a retrospective, multicenter observational study.
    Nakagawa J; Koyama Y; Kawakami A; Ueki Y; Tsukamoto H; Horiuchi T; Nagano S; Uchino A; Ota T; Akahoshi M; Akashi K
    Arthritis Res Ther; 2017 Aug; 19(1):185. PubMed ID: 28800780
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of disease-mediated therapeutic protein-drug interactions between an anti-interleukin-6 monoclonal antibody (sirukumab) and cytochrome P450 activities in a phase 1 study in patients with rheumatoid arthritis using a cocktail approach.
    Zhuang Y; de Vries DE; Xu Z; Marciniak SJ; Chen D; Leon F; Davis HM; Zhou H
    J Clin Pharmacol; 2015 Dec; 55(12):1386-94. PubMed ID: 26054042
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of tildrakizumab (MK-3222), a high affinity, selective anti-IL23p19 monoclonal antibody, on cytochrome P450 metabolism in subjects with moderate to severe psoriasis.
    Khalilieh S; Hussain A; Montgomery D; Levine V; Shaw PM; Bodrug I; Mekokishvili L; Bailey-Smith C; Glasgow XS; Cheng A; Martinho M; Iwamoto M
    Br J Clin Pharmacol; 2018 Oct; 84(10):2292-2302. PubMed ID: 29926968
    [TBL] [Abstract][Full Text] [Related]  

  • 11. AT-rich-interactive domain-containing protein 5A functions as a negative regulator of retinoic acid receptor-related orphan nuclear receptor γt-induced Th17 cell differentiation.
    Saito Y; Kagami S; Sanayama Y; Ikeda K; Suto A; Kashiwakuma D; Furuta S; Iwamoto I; Nonaka K; Ohara O; Nakajima H
    Arthritis Rheumatol; 2014 May; 66(5):1185-94. PubMed ID: 24782182
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systematic review of tocilizumab for rheumatoid arthritis: a new biologic agent targeting the interleukin-6 receptor.
    Navarro-Millán I; Singh JA; Curtis JR
    Clin Ther; 2012 Apr; 34(4):788-802.e3. PubMed ID: 22444783
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Simulating the Impact of Elevated Levels of Interleukin-6 on the Pharmacokinetics of Various CYP450 Substrates in Patients with Neuromyelitis Optica or Neuromyelitis Optica Spectrum Disorders in Different Ethnic Populations.
    Machavaram KK; Endo-Tsukude C; Terao K; Gill KL; Hatley OJ; Gardner I; Parrott N; Ducray PS
    AAPS J; 2019 Mar; 21(3):42. PubMed ID: 30887238
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum interleukin 6 before and after therapy with tocilizumab is a principal biomarker in patients with rheumatoid arthritis.
    Shimamoto K; Ito T; Ozaki Y; Amuro H; Tanaka A; Nishizawa T; Son Y; Inaba M; Nomura S
    J Rheumatol; 2013 Jul; 40(7):1074-81. PubMed ID: 23637318
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of a Physiologically Based Pharmacokinetic Model to Predict Disease-Mediated Therapeutic Protein-Drug Interactions: Modulation of Multiple Cytochrome P450 Enzymes by Interleukin-6.
    Jiang X; Zhuang Y; Xu Z; Wang W; Zhou H
    AAPS J; 2016 May; 18(3):767-76. PubMed ID: 26961818
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A new bioassay for measuring the strength of IL-6/STAT3 signal inhibition by tocilizumab in patients with rheumatoid arthritis.
    Saito S; Suzuki K; Yoshimoto K; Kaneko Y; Matsumoto Y; Yamaoka K; Takeuchi T
    Arthritis Res Ther; 2017 Oct; 19(1):231. PubMed ID: 29041951
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non-autoimmune combined factor XIII A and B subunit deficiencies in rheumatoid arthritis patients treated with anti-interleukin-6 receptor monoclonal antibody (tocilizumab).
    Souri M; Mokuda S; Inanami H; Osaki T; Takasugi K; Ichinose A
    Thromb Res; 2016 Apr; 140():100-105. PubMed ID: 26938156
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic drug interactions between clobazam and drugs metabolized by cytochrome P450 isoenzymes.
    Walzer M; Bekersky I; Blum RA; Tolbert D
    Pharmacotherapy; 2012 Apr; 32(4):340-53. PubMed ID: 22422635
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tocilizumab, a humanized anti-IL-6R antibody, as an emerging therapeutic option for rheumatoid arthritis: molecular and cellular mechanistic insights.
    Hashizume M; Tan SL; Takano J; Ohsawa K; Hasada I; Hanasaki A; Ito I; Mihara M; Nishida K
    Int Rev Immunol; 2015 May; 34(3):265-79. PubMed ID: 25099958
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tocilizumab and mesenteric arterial thrombosis: drug-drug interaction with anticoagulants metabolized by CYP 450 and/or by P-glycoprotein.
    Clarivet B; Robin P; Pers YM; Ferreira R; Lebrun J; Jorgensen C; Hillaire-Buys D; Brés V; Faillie JL
    Eur J Clin Pharmacol; 2016 Nov; 72(11):1413-1414. PubMed ID: 27457374
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.